AstraZeneca's Crestor May Harm Kidneys  WASHINGTON (Reuters) - Twenty-nine patients who took  AstraZeneca Plc's &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=AZN.L target=/stocks/quickinfo/fullquote"&gt;AZN.L&lt;/A&gt; &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=AZN.N target=/stocks/quickinfo/fullquote"&gt;AZN.N&lt;/A&gt; anti-cholesterol drug Crestor  have developed kidney damage, a U.S. consumer group said on  Friday as it called again for a ban on the medicine.